Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology [Yahoo! Finance]
Oncology Specimen Provider Reference Medicine Announces Launch of Characterized Specimens, Enabling Increased Speed and Efficiency for Assay Developers
Fulgent Genetics, Inc. (NASDAQ: FLGT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Fulgent Genetics, Inc. (NASDAQ: FLGT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Fulgent Genetics, Inc. (NASDAQ: FLGT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.